What Firefly Bio does

Firefly Bio was a preclinical-stage biotechnology company developing targeted cancer therapeutics based on Degrader Antibody Conjugate (DAC) technology, with its proprietary Firelink platform as the sole core asset. The platform combines antibody-drug conjugate (ADC) targeting with catalytic protein degraders as payloads, joined via the company's proprietary Firelink linker technology. This architecture was designed to overcome two structural limitations of existing modalities: the narrow therapeutic index of traditional cytotoxic ADC payloads and the lack of cell-specific delivery for systemic protein degraders. The linker reduces free payload in circulation and minimizes uptake in healthy cells, enabling lower efficacious doses and selective knockdown of intracellular oncoproteins — including previously 'undruggable' targets such as KRAS-driven drivers in hard-to-treat solid tumors. Preclinical studies reported significant tumor volume reductions at very low doses across solid and liquid tumor models, with efficacy observed after single administration.

The company's primary customer segment was biopharmaceutical partners and large pharmaceutical companies seeking next-generation ADC payloads to expand oncology pipelines. Firefly did not commercialize any products and operated a preclinical asset-development model with revenue mechanics anticipated through strategic partnerships, licensing, or acquisition by a larger pharmaceutical company. The go-to-market was science-driven and B2B, relying on press releases, scientific publications, industry conferences (including the BIO International Convention), and LinkedIn for visibility rather than traditional sales channels.

Firefly Bio was founded in 2024 (emerging from stealth in February 2024 with a $94 million Series A co-led by Versant Ventures and MPM BioImpact, with participation from Decheng Capital and Eli Lilly & Company) and headquartered in South San Francisco, California with 11-50 employees. The founding team included Nobel laureate Carolyn Bertozzi as co-founder, alongside a leadership bench drawn from Genentech, AbbVie, NGM Bio, Silverback Therapeutics, Pfizer/Seagen, and Allakos. In June 2026 Johnson & Johnson announced a definitive agreement to acquire Firefly for $1 billion in cash, completing the transaction on July 29, 2026 and integrating the team into J&J's Innovative Medicine division. As of acquisition close, Firefly Bio ceased to operate as an independent entity.

Name

Firefly Bio

Legal name

Firefly Bio, Inc.

Website

https://fireflybiologics.com

Company type

Private

Founded year

2022

Operating status

Acquired

Headcount range

11–50 employees

Short description

Firefly Bio was a preclinical-stage biotechnology company developing Degrader Antibody Conjugates (DACs), combining antibody-drug conjugate targeting with catalytic protein degraders via its proprietary Firelink linker to treat KRAS-driven solid tumors. It was acquired by Johnson & Johnson for $1 billion in July 2026.

Ownership category

akta.pro rank

Product category

Cancer Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Antibody drug conjugates
• Degrader antibody conjugates
• Targeted cancer therapy
• Oncology drug development
• Protein degrader payloads

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Technology Development / Platform Licensing: Pre-revenue biotech company focused on developing its Firelink DAC platform for cancer treatment. Revenue model anticipated through strategic partnerships, licensing deals, or acquisition by larger pharmaceutical companies, as evidenced by the Johnson & Johnson acquisition for $1 billion in 2026.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Firefly Bio develops a proprietary Degrader Antibody Conjugate (DAC) platform called Firelink™ that combines antibody drug conjugate (ADC) technology with catalytic protein degraders. The platform enables targeted delivery of protein degraders directly to cancer cells, particularly KRAS-driven solid tumors, while minimizing uptake in healthy cells through the proprietary Firelink linker technology. The technology was advanced through preclinical development toward strategic partnership or acquisition by larger pharmaceutical companies.

Product overview

Firefly Bio offers a single unified platform product — the Firelink™ Degrader Antibody Conjugate (DAC) platform — designed for targeted cancer therapy. The platform combines the strengths of antibody drug conjugates (ADCs) with protein degraders, overcoming limitations of each approach. It enables selective delivery of protein degraders to tumor cells while sparing healthy tissue, addressing previously 'undruggable' targets including KRAS-driven cancers.

Differentiator

Problem solved

Functional benefit

Brands

• Firelink™: Proprietary degrader antibody conjugate (DAC) platform technology for delivering protein degraders directly to cancer cells

Products and services

• Firelink™ Degrader Antibody Conjugate Platform A proprietary platform combining antibody drug conjugates (ADCs) with selective protein degraders, enabling targeted delivery of catalytic protein degraders directly to cancer cells while minimizing uptake in healthy cells. The Firelink linker technology reduces free payload in circulation and lowers doses needed for optimal efficacy. The platform is designed to address KRAS-driven solid tumors and other previously undruggable cancer targets through catalytic protein knockdown.

Quantifiable outcome

• Significant tumor volume reductions at very low doses in preclinical studies across solid and liquid tumor models
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Johnson & Johnsoncore/flagshipStrategic or Co-development Partner · 8 June 2026Johnson & Johnson entered into a definitive agreement to acquire Firefly Bio for $1 billion in cash, gaining access to the Firelink DAC platform. The acquisition was completed on July 29, 2026. The Firefly team was integrated into J&J's Innovative Medicine division to accelerate development of targeted cancer treatments for solid tumors including KRAS-driven cancers.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Arvinas: Pioneer in targeted protein degradation (PROTACs) and now developing antibody-targeted degrader conjugates. Most directly comparable to Firefly because it combines antibody-based targeting with catalytic protein degradation — the same conceptual architecture underlying Firelink DACs.
• Kymera Therapeutics: Clinical-stage protein degrader company (PROTAC-based) developing degrader therapeutics for oncology and immunology. Comparable to Firefly because it operates in the targeted protein degradation category that Firefly's payload chemistry exploits, and pursues similar intracellular 'undruggable' targets.
• Mersana Therapeutics: Clinical-stage ADC developer using novel payload classes (Dolaflexin, Dolasynthen platforms) including immuno-stimulatory and bystander-active payloads. Comparable to Firefly because it competes in next-generation payload ADCs beyond MMAE/DM1/DXd, where Firefly's protein-degrader payload would also be positioned.
• C4 Therapeutics: Clinical-stage targeted protein degradation company developing both small-molecule degraders (MonoDACs) and antibody-conjugated degraders. Highly relevant because it explicitly operates in the protein-degrader-payload category that Firefly's Firelink platform is built around.

Broad incumbents

• Daiichi Sankyo: Global ADC leader (Enhertu, Datroway) that has driven the modern ADC field. Relevant because Firefly's DACs will compete in the same oncology indications where Daiichi Sankyo's cytotoxic payload ADCs have established efficacy and safety benchmarks.
• ImmunoGen (AbbVie): Established ADC developer (Elahere for ovarian cancer) acquired by AbbVie for $10.1B in 2024. Directly relevant as an ADC platform that proved the strategic-acquisition value of differentiated ADC technology — the same exit pathway Firefly followed with J&J.
• Seagen (Pfizer): Pioneer ADC company (Adcetris, Padcev, Tukysa, Tivdak) acquired by Pfizer for $43B in 2023. Comparable as a benchmark for ADC-platform valuation and as a competitor whose established ADC franchise sets the bar Firefly-derived assets must clear in solid tumors.

Emerging players

• Bolt Biotherapeutics: Clinical-stage developer of immune-stimulating antibody conjugates (ISACs) — a novel ADC payload category similar in spirit to Firefly's protein-degrader payloads. Comparable as a peer exploring non-cytotoxic ADC mechanisms to overcome the therapeutic-index ceiling of traditional ADCs.
• Pyxis Oncology: Clinical-stage ADC developer with a next-generation payload platform including microtubule-inhibitor and topoisomerase-based ADCs. Comparable as a smaller ADC-platform peer pursuing novel payload chemistries to differentiate from incumbent cytotoxic ADCs.
• Tubulis: European ADC developer with proprietary linker chemistry and a pipeline of differentiated ADC candidates. Comparable to Firefly because Firelink is fundamentally a novel linker-payload architecture, and Tubulis pursues a similar 'differentiated linker as competitive edge' strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/firefly-biologics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Firefly Bio